By: IPP Bureau
Last updated : September 30, 2025 9:55 am
Miels will formally assume the role on January 1, 2026
British drugmaker GSK on Monday named Luke Miels as its CEO designate. He will take over from Emma Walmsley, who steps down after nine years leading the company.
Miels will formally assume the role on January 1. He will be responsible for steering GSK towards its target of generating more than 40 billion pounds ($53.78 billion) in annual sales by 2031.
Miels joined GSK in 2017 and is currently Chief Commercial Officer, with world-wide responsibility for medicines and vaccines. He has been instrumental in building GSK’s specialty medicines portfolio, notably in oncology and respiratory.
Miels is a highly respected, experienced global biopharma leader, having worked at senior levels in the US, Europe and Asia, at AstraZeneca, Roche and Sanofi-Aventis, prior to joining GSK.
This experience, and significant contribution to GSK, mean he is exceptionally well-qualified to lead the company, and to deliver the patient and shareholder value inherent in the company’s future ambitions.
Emma will step down from the Board on 31st December 2025. She will remain with the business until her notice period ends on 30 September 2026 and will support an orderly transition throughout that period. In addition, given the potential impact to GSK’s operating environment arising from geopolitics and new technologies, the Board has asked Emma to support the company and the new CEO on these matters.